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EDITORIAL
MULTI DRUG RESISTANT TUBERCULOSIS
Tuberculosis (TB) is the leading cause of death
among people who are HIV-positive. Approximately
one-third of the nearly 40 million people living with
HIV/AIDS are also infected with TB. In areas such
as sub-Saharan Africa, up to half of the AIDS-related
deaths are caused by TB. During the early 1990s,
multidrug-resistant tuberculosis (MDR TB), defined
as resistance to at least isoniasid and rifampicin, the
two most powerful anti-tuberculosis drugs emerged
as a threat to TB control worldwide (1). The numerous
outbreaks of MDR TB reported from many different
countries located in diverse geographical
environments during this time were indications of a
global epidemic. Between 1994 and 2002, the WHO
Global Project on Anti-TB Drug Resistance
Surveillance coordinated data collection on more than
250,000 patients from 109 countries (or regions within
large countries), representing 42% of the world’s
population (2). On this basis, WHO estimated the
annual burden of MDR TB to be approximately
300,000-600,000 cases and the prevalence of MDR
TB to be threefold higher than the annual incidence,
primarily in low and middle-income countries.
Mortality is significantly greater in HIV positive
patients with MDR TB than those who are HIV
negative (2-4).  Very recently, the sudden emergency
of XDR TB has become a significant cause for
concern globally. XDR TB is defined as extensively
drug resistant TB that is resistant to at least three of
the six classes of the available second-line drugs, in
addition to MDR TB (5).
In Kenya, findings from the 1995 anti-TB drug
resistance surveillance showed that despite
increasing prevalence of both TB and HIV-I
infections, rates of initial drug resistance were still
low and no MDR TB was reported (6). However,
earlier results indicated that levels of drug resistance
and MDR TB were higher in the refugee population
than in the surrounding non refugee community in
North-Eastern Province (7).  Ten years later, MDR
TB strains were first described in an indigenous
patient population from private and public health
care facilities in Nairobi (8,9).  MDR TB has also been
observed in the last national anti-TB drug resistance
surveillance conducted in 2002 (10), exactly 10 years
since the introduction of Direct Observed Therapy
Short course (DOTS) in the country.  DOTS is a first-
line drug regimen that includes isoniazid and
rifampicin.
Drug resistance is largely a man-made
phenomenon and is a consequence of suboptimal
regimens and treatment interruptions.  Other factors
that commonly lead to development and
transmission of MDR TB include HIV seropositivity,
poverty and overcrowding, mixing of persons with
TB not responding to therapy with HIV-infected
persons in crowded hospital wards and clinics,
failure to provide effective treatment support and
assurance of adherence; failure to recognise and
address patient non-adherence; adding a single new
drug to a failing regimen and failure to recognise
existing drug resistance (2,11).
Patients with MDR TB are difficult to cure
because they require prolonged hospitalisation and
the use of second-line drugs that are toxic and more
costly than first-line based regimens (2). The price
of most second-line antituberculosis drugs
recommended for use in the treatment of MDR TB
is unaffordable to countries in need. In Kenya, it is
currently estimated that over US $18,000 is required
to treat a single case of MDR TB (Sitienei, personal
communication, 2006) compared to approximately
US $ 400 required to treat a non MDR TB case.
In 2000, the WHO-based Stop TB Partnership’s
Green Light Committee (GLC) was created to
increase access to second-line drugs worldwide
while ensuring their proper use to prevent the
spread of increased drug resistance. During the time,
this Scientific Panel of the WHO Working Group on
DOTS-Plus for MDR TB produced its first set of
guidelines – Guidelines for establishing DOTS-Plus
pilot projects for the management of multidrug-resistant
tuberculosis –  which were reviewed in 2005 (2). The
new guidelines provide guidance on current best
practice in the management of drug-resistant TB,
especially MDR TB, that should be adopted
worldwide. It is emphasised that these
recommendations should be followed without
hesitation by all national TB control programmes
and their partners as the most solid programmatic
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standards. At the same time, it is important to
highlight that the new global TB control strategy
remain the cornerstone of TB control and the most
effective tool for preventing the onset and
dissemination of drug resistance. The overall TB
control strategy will consist of six key components.
The first DOTS strategy’s key elements will include
political commitment, passive case finding,
standardised chemotherapy, regular supply of drugs
and monitoring and evaluation. The other key
components of the control strategy include MDR
TB/HIV and emerging challenges, involvement of
all stakeholders – Public-Private Mix (PPM),
strengthening of health care systems, involvement
of communities and patients (patient charter) and
operational research. Without these essential
elements of TB control fully in place, management of
MDR TB will undoubtedly fail in the long term (2).
While new strategies for containing MDR TB are
now in place, the emergency of XDR TB is reported
to have a wide geographic distribution and is
associated with worse treatment outcomes than
MDR TB (MMWR) (11). In Africa, virulent strains
of TB  resistant to all standard drugs have killed 52
of 53 patients in a rural hospital in South Africa in
recent months (12). This super-resistant strain of TB
has up to now been very rare, making an outbreak
in 53 people catastrophic. While resistant TB often
arises from incomplete or ineffective drug treatment,
surprisingly, half of the patients with MDR TB in
South Africa had never been treated for TB before, a
perturbing sign that they were newly infected with
the extreme strain and that XDR is swiftly being
transmitted in the community.  Furthermore, 44%
of the patients were HIV-positive, severely immuno-
compromised and resulted in 98% of them dying
within one month of submitting an initial sputum
sample. The median survival time was a mere 16
days. In the same outbreak, two healthcare workers
also died of MDR TB. In addition to this, very
recently, a report in a Kenyan local newspaper
indicates that 263 cases with at least 30 new cases of
XDR TB are being reported each month in KwaZulu-
Natal,  where almost 40% of the adult population is
HIV infected (13). The situation in other African
countries is yet to be known.
In the only previously-published study on the
XDR strain, the U.S. Centers for Disease Control
(CDC) and Prevention earlier this year reported that
from 2000 to 2004, the combined efforts of CDC and
the WHO surveyed 17,690 collected samples of TB
bacillus from the world’s TB laboratories, and found
a total of 353 cases or 2% of the collected patient
samples were XDR (MMWR) (5). While TB is believed
to kill about 2 million people worldwide each year, a
growing number and proportion of XDR TB cases
could seriously hamper TB control globally. Countries
with good TB programmes have reported possible
cure for XDR TB of only between 50% and 60%.
In spite of the fact that the extent of drug
resistance is still unknown in many countries and
management of patients with MDR TB remains
inadequate, in countries such as Kenya where drug
MDR TB has been identified, specific measures need
to be taken within TB control programmes to address
the problem through appropriate management of
patients and adoption of strategies to prevent the
propagation and dissemination of drug-resistant TB,
including both MDR TB and XDR TB.  In addition
to this, MDR TB and XDR TB can be prevented by
ensuring that the national TB programmes and
healthcare workers dealing with people with TB
both in public and private sectors work in
accordance with acceptable international standards
for TB care. It is imperative to note that all the drugs
used for treating TB have been in use for a long time
and if they are not properly used, tubercle resistance
to them will develop.
Therefore, appropriate use of these drugs for
early treatment, in conjunction with adjunct
measures such as early diagnosis and isolation of
infectious cases must be ensured in order to contain
the emergence of both MDR TB and XDR TB
epidemics.  Nevertheless, existing methods for drug
susceptibility testing  (DST) of second-line drugs for
treatment of  MDR TB are not only less reproducible
than tests for susceptibility to first-line drugs but
are also time consuming and this leads to further
delays in obtaining results (14). Furthermore, WHO
recommends that DST should be performed in
specialised reference laboratories that participate in
the current, rigorous quality assurance programme
(1, 2). These facilities are not uniformly available in
many resource-limited settings.  In view of this,
establishment and scaling up laboratory capacity is
an immediate requisite. This approach will greatly
improve detection and management of both drug
susceptible and resistant TB (15).
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